The integration of Celgene Corp.’s research, discovery, preclinical and early clinical development programs into Bristol-Myers Squibb Co.’s R&D pipeline is almost complete, but the combined company still is looking to add new drug candidates and technologies from external partners, Bristol’s Rupert Vessey, executive vice president of research and early development, told Scrip in a recent interview.
BMS/Celgene Post-Merger Early R&D Strategy: Partnerships Are Still Key, Vessey Says
Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.
More from Deals
• By
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.